Clinical Industry Analytics Report 2020

“You never change things by fighting the existing reality. To change something, build a new model” Our latest industry analytics report features analysis on the clinical sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “Covid19 has been a global disruptor in literally every section of society. However, for the future

Continue Reading

AstraZeneca and Oxford Unis COVID-19 vaccine proves promising

A highly anticipated COVID-19 vaccine which is being jointly developed by AstraZeneca and Oxford University has produced encouraging results in a phase 1/2 trial. The phase 1/2 results, published in The Lancet demonstrated that the vaccine, AZD1222, produced a robust immune response against the SARS-CoV-2 virus in all participants in the study. The vaccine also proved safe to use,

Continue Reading

Clinical Professionals invitation to “Perspectives on the Future of STEM in the UK” Webinar Series

Date: Thursday, July 2nd Time: 12pm In conjunction with CPL’s Future of Work Institute and Cpl Specialist Talent, the Clinical Professionals Group  invites you to our UK based Webinar Series “Perspectives on the Future of STEM”. During these times the world of work is changing for every industry, and STEM (Science, Technology, Engineering & Mathematics.)  is no

Continue Reading

“The most important thing is transforming our minds, for a new way of thinking, a new outlook: should we strive to develop a new inner world?” – Procurement Industry Analytics Report

Our latest industry analytics report features analysis on the procurement sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “As control of spend becomes more prominent in biopharmaceutical management’s message to the investor community, attention has been focused heavily again to the finance portfolio and most prominently through sourcing and procurement.

Continue Reading

AstraZeneca set to start COVID-19 antibody trials

AstraZeneca will start clinical trials of two antibodies targeting SARS-CoV-2, the virus that causes COVID-19, within the next two months. The two candidates have emerged from a partnership with Vanderbilt University in the US – focusing on up to six coronavirus-targeting neutralising antibodies – which was signed in April. The antibodies have the potential to

Continue Reading

Eli Lily commences trial for COVID-19 antibody treatment

Eli Lilly has recently begun dosing patients in the world’s first trial for treatment designed to attack SARS-CoV-2, the virus that causes COVID-19. This investigational treatment, referred to as LY-CoV555, is the first produced as a result of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Scientists developed

Continue Reading